Home / Press Release / Bioasis And Bioagilytix With Their Strategic Alliance Are Expected To Develop The xB3 TM-001 Program Together And Augment Their Position In Blood-Brain Barrier Market

Bioasis And Bioagilytix With Their Strategic Alliance Are Expected To Develop The xB3 TM-001 Program Together And Augment Their Position In Blood-Brain Barrier Market

On 11th July 2018, Bioasis Technologies, Inc. and BioAgilytix announced strategic collaboration to carryout validation & development of bioanalytical methods to assist & support the xB3 TM-001 program that involves treatment of HER2+ brain cancer. The process of validation and development is of utmost importance for ensuring and supporting regulatory approval of the IND and clinical pharmacokinetic details to confirm its maximum therapeutic benefit in Phase I patients and consecutive phases.

BioAgilytix is one of the leading providers of contract bioanalytical testing services and specialized in bioanalysis of large molecules. BioAgilytix has laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany. The Company provides immunogenicity, PK, cell-based assay services, and biomarkers assisting the growth and release testing of biologics across several industries.

Bioasis Technologies, Inc. is creating a proprietary platform to deliver drugs through blood-brain barrier currently named as xB3 specifically focusing on treatment of CNS disorders, brain cancers and neurodegenerative diseases. The Company is headquartered in Richmond Canada with other offices in Guilford, Conn., United States.

Analyst View:

Strategic alliances in the significantly growing market has always benefited widely as the experts from both companies try to implement their knowledge and experience to develop a complete and enhanced molecule or platform to treat chronic diseases. Thus, in blood-brain barrier market this strategic alliance is expected to exhibit prominent effect because Bioasis Technologies is one of the major companies in blood-brain barrier market and with this alliance Bioasis will swiftly advance its xB3 TM-001 program to introduce novel treatments to patients suffering with brain cancer. In addition, through this partnership Bioasis will have access to BioAgilytix’s broad bioanalytical expertise specifically in anti-drug antibody detection, top-notch quality GLP validation of complex assays, ligand binding assays, and stability assessments across complex matrices. Thus, a trend of alliances and partnerships is expected to be observed in blood-brain barrier market.

Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on Rss
Add us on Google +